BTIG analyst Ryan Zimmerman raised the firm’s price target on Alcon to $91 from $88 and keeps a Buy rating on the shares. MedTech performance in 2Q23 improved sequentially, up 4.6%, and was the best performing Healthcare sub-sector again, but returns were not as robust as the firm expected for the broader group against such a strong fundamental backdrop, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>